KALA BIO Inc expected to post a loss of $1.70 a share - Earnings Preview
KALA BIO Inc
KALA is expected to show no change in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025LSEG's mean analyst estimate for KALA BIO Inc is for a loss of $1.70 per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for KALA BIO Inc is $12.00, about 43.6% above its last closing price of $6.77
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.99 | -2.03 | -1.41 | Beat | 30.5 |
Dec. 31 2025 | -2.28 | -1.74 | Beat | 23.7 | |
Sep. 30 2024 | -2.25 | -2.43 | -1.93 | Beat | 20.6 |
Jun. 30 2024 | -4.29 | -4.40 | -3.16 | Beat | 28.3 |
Mar. 31 2024 | -3.02 | -2.89 | -4.19 | Missed | -45 |
Dec. 31 2023 | -3.62 | -3.18 | Beat | 12.2 | |
Sep. 30 2023 | -2.32 | -2.15 | -3.41 | Missed | -58.3 |
Jun. 30 2023 | -2.82 | -3.19 | -4.36 | Missed | -36.8 |
This summary was machine generated August 1 at 13:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
